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Abstract--Anti platelet and antithrombotic effects of OP-41483, a PG12 analog, were studied in experimental animals, and the following results were obtained: 1) With 10 min-intravenous infusion to guinea pigs, OP-41483 inhibited platelet adhesiveness and platelet aggregation at 300-1000 ng/kg/min and 1000 ng/kg/ min, respectively. In these effects, OP-41483 was 1-3 times more potent than carbacyclin and 3 times less potent than PGI2. 2) With oral administration to guinea pigs, OP-41483 given as its a-cyclodextrin clathrate (OP-41483 a-CD) inhibited platelet adhesiveness at doses higher than 1.0 mg/kg (expressed in terms of OP-41483), whereas PGI2 and carbacyclin did not at 10 mg/kg. OP-41483 a-CD also inhibited platelet aggregation after a single dose of 3 mg/kg and repeated doses of 3 mg/kg/day for 7 days. 3) In the electrically induced thrombosis model of guinea pig mesenteric artery, OP-41483 (300-1000 ng/kg/min, i.v.-infusion) and OP-41483 a-CD (1.0-3.0 mg/kg, p.o.) inhibited thrombus formation, but heparin (1.0-10 U,/kg/min, i.v.-infusion) did not. 4) In the rabbit extracorporeal circulation thrombosis model, OP-41483 (100 and 300 ng/kg/min, i.v.-infusion) inhibited thrombus formation in the extracorporeal shunt and prevented the decrease in platelet count, hematocrit and fibrinogen level in circulating blood. Heparin (1.0-3.0 U/kg/min, i.v.-infusion) also inhibited the thrombus formation and the decrease in fibrinogen level, but did not inhibit the decrease in hematocrit and platelet count.
The application of prostaglandin 12 (PG!2) for the treatment of thrombotic or ischemic vascular diseases has attracted attention be cause of its potent antiplatelet (1) and vaso dilating effects (2) . However, its instability in aqueous media makes its clinical use difficult, particularly in the form of oral application. There have been some attempts, therefore, to explore chemically stable PGI2 analogs (3). OP-41483, 5-(E)-6,9-deoxa-6,9a-methy lene -15 cyclopentyl -16,17,18,19,20 penta nor-PG12 ( Fig. 1) , is a new, chemically stable PG12 analog with an antiplatelet effect (4). Adaikan et al. have previously shown that OP-41483 inhibits platelet aggregation in monkeys (5) and humans (6) without any effect on blood pressure and heart rate. This suggests that OP-41 483 may have antithrom botic properties favorable for the treatment of thrombotic and ischemic vascular diseases.
In the present study, we compared the anti platelet of OP-41483 with that of PG12 and carbacyclin in guinea pigs ex vivo, and we examined the antithrombotic effects of OP 41483 in guinea pig and rabbit thrombosis models in comparison with those of PG12, carbacyclin and the anticoagulant heparin.
Materials and Methods
Animals: Male guinea pigs of the Hartley strain weighing 300-650 g and male white rabbits weighing 2.5-3.5 kg were used. Diet and water were given ad libitum.
Test compounds: OP-41483, PG 12 and carbacyclin were dissolved in a small amount of ethanol and then diluted with 0.1 M glycine-NaOH buffer (pH 10.0) for in travenous infusion or 0.5% tragacanth solu tion for oral administration. OP-41483 was orally given in the form of its a-cyclodextrin clathrate (OP-41 483 a-CD) containing 2.78% OP-41483 because it gave solutions of high OP-41483 concentration. OP-41483 a-CD was dissolved in 0.9% saline, and the dose was expressed in terms of its active principle OP-41483. Oral activity of OP-41483 and OP-41483 a-CD was similar with regards to the inhibition of platelet adhesiveness in guinea pigs (Data are not shown).
Platelet function studies: After the guinea pigs were anesthetized by pentobarbital sodium (50 mg/kg, i.p.), blood was collected into plastic syringes by cardiac puncture in the oral route experiment or from the vena cava in the intravenous infusion experiment. The plastic syringes for blood collection contained 1 volume of 3.8% trisodium citrate or 30 U/ ml heparin to 9 volumes of blood. Test com pounds were given orally or infused into the jugular vein.
Platelet adhesiveness was estimated by the previously described method (7). Heparinized blood was passed through a column con taining 0.5 g of glass beads (Igakushoin Kikai Co. Ltd., Japan) at a flow rate of 1.0 ml /min. The second one ml-aliquot of effluent blood from the column was used for platelet count ing. Platelet adhesiveness was calculated as follows: Platelet adhesiveness (%)=(A-B)/ Ax 100, where A is the platelet count in blood before the column passage and B is the count in the colmun-passed blood.
Platelet aggregation was examined by a turbidimetric method (8) using an aggrego meter (Hematracer VI, Niko Bioscience, Japan). Platelet-rich and platelet-poor plasma were prepared by centrifugation of citrated blood at 120 x g for 10 min and 1100 x g for 10 min, respectively. Platelet count in the platelet-rich plasma was adjusted to 5x105_ 6x105 cel Is/mm3 with the platelet-poor plasma. The platelet-rich plasma (237.5 ,al) was preincubated at 37'C for 1 min and then aggregation was induced by adding ADP or collagen (12.5 ,ul). The extent of aggregation was assessed by the maximum change of light transmittance within 5 min after adding ADP and collagen.
Electrically induced thrombosis in guinea pigs: Thrombosis was electrically induced in the guinea pig mesenteric artery by the pre viously described method (9). Guinea pigs anesthetized with pentobarbital sodium (75 mg/kg, s.c.) were subjected to abdominal incision. The jejunum part of the intestinal loops was extended over a plastic plate, and the mesentery was superfused with saline (37 °C). A platinum electrode (200 am in diameter with shapened tip) as an anode was touched to the mesenteric artery (30-60 acm in diameter), and a cathodal electrode was fixed to the edge of the incision. Then, the mesenteric artery was electrically stimulated with a single rectangular pulse (pulse dura tion of 1000 msec). The voltage of the stimu lation was changed in a stepwise manner at 2.5 V intervals (5-30 V). The thrombus forma tion was microscopically observed for 10 min after each stimulation, and the lowest voltage causing complete occlusion of the vessel by thrombi (threshold voltage for thrombus for mation) was determined. The drug-effect was assessed by the change of the threshold voltage. Test compounds were given orally 30 min before or infused into the jugular vein from 10 min before the electrical stimulation.
Extracorporeal shunt thrombosis in rabbits: The extracorporeal shunt was made of a polyethylene column (11.4 cm in length and 0.85 cm in inner diameter), and both of its ends were connected to polyethylene tubings (2.5 mm in inner diameter). The volume of the shunt was 7.6 ml. After rabbits were anesthetized with pentobarbital sodium (50 mg/kg, s.c.), the extracorporeal shunt was inserted between the right carotid artery and the left jugular vein, and blood was allowed to circulate through the shunt for 2 hr. OP-41 483 and/or heparin were continuously infused into the ear vein from 30 min before the start of extracorporeal ciculation. At the end of the extracorporeal circulation, the shunt was removed for estimating thrombus volume and, at the same time, blood was withdrawn from the femoral artery for estimating platelet count, hematocrit, whole blood clotting time and plasma fibrinogen level in the circulating blood.
Platelet count: Platelet count in citrated blood was estimated using a platelet counter (PL-100, Toa Medical Electronics Co., Japan).
Fibrinogen level: Citrated plasma was diluted 25-50 fold with 0.85% NaCI. Diluted plasma (5 ml) was incubated with 100 U/ml of thrombin (0.1 ml) and 0.2 M CaCl2 (0.1 ml) at 37 °C for 1 hr to clot fibrinogen. After sepa rating the clotted protein, its amount was Whole blood clotting time: Native whole blood was placed in a glass tube, and the time for the formation of a clot was photometri cally measured according to the method of Lee and White (11) using a coagulometer (model TE15, Erma Kogaku, Japan).
Hematocrit: Hematocrit values were meas ured after centrifuging blood in a glass capillary tube at 10000 rpm for 5 min in a centrifuge (MC-101, Hitachi Ltd., Japan).
Chemicals: PG12, carbacyclin, OP-41483 and OP-41483 a-CD were synthetized by Ono Pharmaceutical
Co., Ltd., Japan. Heparin was obtained from Dainippon Pharmaceutical Co., Ltd., Japan. Nifedipine was obtained from Bayer Japan
Co., Ltd., Japan. ADP, thrombin and collagen (from bovine Achilles tendon)
were obtained from Sigma Chem. Co., U.S.A.
Statistical analysis: The statistical signifi cance was evaluated by Student's t-test.
Results

Effect on platelet functions
Intravenous infusion: A ten min-intra venous infusion of OP-41483 markedly in hibited platelet adhesiveness in a dose dependent manner, and the doses required for significant inhibition were 300-1000 ng/ kg/min ( Table 1 ). The inhibitory potency of OP-41483 was comparable to that of car Compounds were infused into the jugular vein for 10 min, and blood samples were collected at the end of the infusion period. bacyclin and 3 times less potent than that of PG12.
OP-41483 at 1000 ng/kg/min also in hibited platelet aggregation induced by ADP and collagen. The inhibitory effect was more potent than that of carbacyclin (Table 2) .
Oral administration: Thirty minutes after oral administration of PGI2 analogs, OP 41483 a-CD inhibited platelet adhesiveness at doses higher than 1.0 mg/kg, but carbacylin and PGI2 did not inhibit it at 10 mg/kg ( Table  3) . As for the duration of inhibitory activity, the effect of OP-41483 a-C D reached its maximum 30 min after administration and lasted for 2 hr (Fig. 2) .
Pletelet aggregation induced by ADP was inhibited by single and 7 day-repeated ad ministrations of OP-41483 a-CD at 3 mg/kg and 3 mg/kg/day, respectively (Table 4) . The inhibitory effect in the single and repeated administrations was very similar. Effect on thrombus formation induced by electrical stimulation in guinea pig mesenteric artery
The threshold voltages for the thrombus formation ranged between 10 and 17.5 V in control animals. Intravenous infusion of OP 41483 at 300-1000 ng/kg/min significantly elevated the threshold voltage for thrombus formation in a dose-dependent manner ( Table  5 ). The antithrombotic effect of OP-41483 was slightly more potent than that of car bacyclin and one-third that of PG12. Heparin at 1.0 and 3.0 U/kg/min did not alter the Compounds were infused into the jugular vein for 10 min, and blood samoles were collected at the end of the infusion period. In the extracorporeal circulation for 2 hr, the shunt was almost completely filled with thrombi.
Platelet count, hematocrit and plasma fibrinogen level in the circulating blood also significantly decreased (Table 6 ). Intravenous infusion of OP-41483 at 100 and 300 ng/kg/min significantly decreased the thrombus formation in the shunt, although no complete inhibition was observed. OP-41 483 also inhibited decreases in platelet count, hematocrit and fibrinogen level in the circu lating blood without any effect on whole blood clotting time. Heparin at doses pro longing the whole blood clotting time (1-3 U/kg/min) prevented thrombus formation and inhibited the decrease in fibrinogen level, but did not inhibit decreases in hematocrit and platelet count. Administration of OP-41483 at 100 ng/kg/min with heparin (1.0 U/kg/ min) was more effective than OP-41 483 alone or heparin alone on preventing thrombus formation, and it was effective for preventing decreases in platelet count and hematocrit in comparison with heparin alone. OP-41483 at 300 ng/kg/min with heparin (1.0 U/kg/ min) completely prevented the thrombus formation and hematological changes ob served in the extracorporeal circulation period.
Discussion
In the present investigation, effects of intravenously and orally administered OP 41483 on platelet adhesiveness, platelet aggregation and thrombus formation were There was no statistical difference in initial values between the control group and the drug treated groups. Compounds were infused from 30 min before starting extracorporeal circulation. studied in experimental animals. The effects of OP-41483 were compared with those of PG12 and carbacyclin, and its antithrombotic effect was compared with that of heparin.
The effects of intravenously infused OP 41483 on platelet functions and thrombus formation were less potent than those of PG12 and comparable to or slightly more potent than those of carbacylin. By oral ad ministration, however, OP-41483 inhibited platelet adhesiveness at doses higher than 1.0 mg/kg, whereas PGI2 and carbacyclin were without effect up to 10 mg/kg. These results indicate that OP-41483 is easily ab sorbed from the gastrointestinal tract and stable in the circulation. As PGI2 is known to rapidly change into 6-keto prostaglandin Fla by undergoing decomposition at its 6,9 epoxy bond and loses its antiplatelet activity in aqueous media, especially in acidic media, it may be decomposed in the stomach and intestine. In contrast, OP-41483 and car bacyclin which have the chemically stable 6,9-metano structure (Fig. 1) Thrombi are classified into two types: the arterial thrombus which is mainly comprised of platelet aggregates and the venous throm bus which is comprised of erythrocytes and fibrin. The formation of arterial thrombi is believed to be efficiently prevented by an tiplatelet agents and that of the venous thrombi, by anticoagulants.
OP-41483 prevented the formation of the arterial thrombus induced by electrical stimu lation in the guinea pig mesenteric artery, but heparin did not. On the other hand, heparin prevented the thrombus formation and inhib ited the decrease in plasma fibrinogen level occurring during extracorporeal circulation in rabbits. In this model, OP-41483 also pre vented the thrombus formation and inhibited the decrease in plasma fibrinogen level with out any effect on clotting time. Furthermore, OP-41483 inhibited the decreases in hema tocrit and platelet count which were not pre vented by heparin. These results indicate that platelet activation is involved in the pri mary process of the activation of the blood coagulation system and also in the thrombus formation in the heparin-effective thrombosis model, and that this platelet activation process is efficiently prevented by OP-41483. The ef fective doses in this model were 3 times lower than those in the guinea pig model. This dif ference may come from a species difference, because the in vitro effect of OP-41483 on rabbit PRP was 3 times more potent than that on guinea pig PRP (data are not shown).
In clinical aspects, these effects of OP 41483 alone and in combination with heparin may be useful for preventing thrombus forma tion associated with extracorporeal circula tion.
In summary, OP-41483 inhibited platelet functions in guinea pigs ex vivo. The effect was evident even in oral administration. It also prevented the thrombus formation in an elec trically induced thrombosis model and in an extracorporeal shunt thrombosis model in ex perimental animals, the models for the arterial and the heparin-effective thrombosis, respec tively. These results suggest that OP-41483 is favorable for the treatment of a variety of thrombotic and ischemic vascular diseases.
